{"id":124,"date":"2026-05-18T17:11:16","date_gmt":"2026-05-18T17:11:16","guid":{"rendered":"https:\/\/actinpeptides.com\/?post_type=product&p=124"},"modified":"2026-08-25T15:49:07","modified_gmt":"2026-08-25T15:49:07","slug":"cjc-1295-ghrp-6-blend-10mg","status":"publish","type":"product","link":"https:\/\/actinpeptides.com\/fr\/product\/cjc-1295-ghrp-6-blend-10mg\/","title":{"rendered":"M\u00e9lange CJC-1295 et GHRP-6 (10 mg)"},"content":{"rendered":"

CJC-1295 & GHRP-6 Peptide Blend<\/h1>\n

Introduction<\/h2>\n

CJC-1295 & GHRP-6 peptide blend<\/strong> combines two synthetic peptides that researchers have studied for their effects on growth hormone signaling. CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), while GHRP-6 is a synthetic growth hormone secretagogue associated with the growth hormone secretagogue receptor (GHS-R1a).<\/p>\n

Research on the individual peptides has examined growth hormone release, insulin-like growth factor-1 (IGF-1) signaling, cellular responses, gastrointestinal activity, and other physiological pathways. However, the available research does not establish that the specific CJC-1295 and GHRP-6 combination produces a clinically meaningful synergistic effect<\/strong>. Therefore, the blend is best understood as a research formulation based on two separately studied growth hormone-related peptides.<\/p>\n

For researchers comparing related compounds, Actin Peptides also offers GHRP-6 peptide<\/a>, IGF-1 LR3 de qualit\u00e9 r\u00e9cepteur<\/a>, and other peptides investigated in growth-factor and cellular-signaling research.<\/p>\n

\n

Aper\u00e7u<\/h2>\n

What is CJC-1295 & GHRP-6?<\/strong><\/p>\n

CJC-1295 and GHRP-6 are synthetic peptides investigated for their ability to influence growth hormone-related signaling through different biological pathways.<\/p>\n

CJC-1295<\/h3>\n

CJC-1295, also described as a modified GRF (1-29) analog, is derived from the first 29 amino acids of growth hormone-releasing hormone. Researchers designed structural modifications within the sequence to alter its stability and pharmacokinetic characteristics.<\/p>\n

Research has investigated CJC-1295 for its effects on growth hormone secretion and downstream IGF-1 signaling.<\/p>\n

GHRP-6<\/h3>\n

GHRP-6 is a synthetic hexapeptide classified as a growth hormone secretagogue. Researchers have studied its interaction with GHS-R1a, a receptor associated with growth hormone secretion.<\/p>\n

Unlike ghrelin, GHRP-6 does not share the same amino-acid sequence. Nevertheless, researchers have investigated its ability to interact with the growth hormone secretagogue receptor system.<\/p>\n

Why combine CJC-1295 and GHRP-6?<\/h3>\n

The rationale for studying the two peptides together comes from their different mechanisms within growth hormone signaling.<\/p>\n

CJC-1295 is associated with the GHRH pathway<\/strong>, whereas GHRP-6 is associated with the growth hormone secretagogue pathway<\/strong>. Researchers have therefore investigated whether activating these pathways together produces a different growth hormone response from either peptide alone.<\/p>\n

Importantly, studies specifically evaluating this commercial blend formulation remain limited.<\/p>\n

\n

CJC-1295 & GHRP-6 Mechanism of Action<\/h2>\n

CJC-1295 and GHRH receptor signaling<\/h3>\n

CJC-1295 is structurally related to the active region of GHRH. Researchers propose that it interacts with GHRH receptors on pituitary cells, initiating intracellular signaling associated with growth hormone secretion.<\/p>\n

The resulting signaling may influence downstream production of IGF-1, an important mediator of several biological effects associated with growth hormone.<\/p>\n

GHRP-6 and GHS-R1a<\/h3>\n

GHRP-6 has been studied as an agonist of the growth hormone secretagogue receptor, commonly designated GHS-R1a<\/strong>.<\/p>\n

Activation of this receptor can participate in signaling that promotes growth hormone release. Researchers have also investigated GHRP-6 in relation to other cellular pathways, including systems involving IGF-1, Akt, and apoptosis-related proteins.<\/p>\n

Potential interaction between the pathways<\/h3>\n

The research rationale for combining the two peptides is based on their different signaling routes:<\/p>\n

CJC-1295 \u2192 GHRH receptor \u2192 growth hormone signaling<\/strong><\/p>\n

GHRP-6 \u2192 GHS-R1a \u2192 growth hormone secretagogue signaling<\/strong><\/p>\n

Because these pathways can interact physiologically, researchers have investigated whether simultaneous stimulation produces a greater growth hormone response.<\/p>\n

However, evidence from studies of individual peptides should not automatically be interpreted as evidence that a particular CJC-1295\/GHRP-6 blend has the same effect.<\/p>\n

\n

CJC-1295 With DAC vs. Without DAC<\/h2>\n

CJC-1295 is commonly discussed in two forms: with DAC<\/strong> et without DAC<\/strong>.<\/p>\n

DAC refers to the Drug Affinity Complex<\/strong>, a structural modification designed to alter the peptide’s interaction with plasma proteins and its pharmacokinetic profile.<\/p>\n

CJC-1295 with DAC<\/h3>\n

Research has investigated the DAC-modified form for prolonged activity and altered plasma persistence. The modification involves attaching a lysine-derived component to the peptide.<\/p>\n

CJC-1295 without DAC<\/h3>\n

The non-DAC form is generally described as a shorter-acting GRF analog because it lacks the additional protein-binding modification.<\/p>\n

Consequently, researchers distinguish the two forms primarily according to their pharmacokinetic characteristics rather than treating them as completely different signaling molecules.<\/p>\n

\n

Composition chimique<\/h2>\n\n\n\n\n\n\n\n\n\n
Property<\/th>\nCJC-1295<\/th>\nGHRP-6<\/th>\n<\/tr>\n<\/thead>\n
Type de peptide<\/td>\nAnalogue modifi\u00e9 de la GHRH<\/td>\ns\u00e9cr\u00e9tagogue de l'hormone de croissance<\/td>\n<\/tr>\n
Molecular Formula<\/td>\nC152H252N44O42<\/td>\nC46H56N12O6<\/td>\n<\/tr>\n
Molecular Weight<\/td>\n3367.9 g\/mol<\/td>\n873.0 g\/mol<\/td>\n<\/tr>\n
Related Names<\/td>\nModified GRF (1-29), CJC-1295 DAC<\/td>\nGrowth Hormone-Releasing Hexapeptide<\/td>\n<\/tr>\n
Primary Research System<\/td>\nGHRH receptor signaling<\/td>\nGHS-R1a signaling<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

The molecular characteristics above describe the individual research compounds rather than a newly occurring biological molecule created by combining the two peptides.<\/p>\n

\n

Recherche et \u00e9tudes cliniques<\/strong><\/h2>\n

CJC-1295 & GHRP-6 Research and Growth Hormone Signaling<\/h2>\n

CJC-1295 and growth hormone levels<\/h3>\n

Study objective:<\/strong>
\nResearchers investigated whether CJC-1295 could influence circulating growth hormone concentrations.<\/p>\n

Methodology:<\/strong>
\nClinical research examined adult male participants who received CJC-1295 or placebo. Researchers collected blood samples before and after peptide exposure.<\/p>\n

Findings:<\/strong>
\nThe reported research observed substantial increases in growth hormone concentrations following CJC-1295 exposure, with changes persisting beyond the immediate observation period.<\/p>\n

Scientific significance:<\/strong>
\nThese findings provide research support for continued investigation of long-acting GHRH analogs and their effects on growth hormone signaling.<\/p>\n

\n

CJC-1295 and Concentration-Dependent Growth Hormone Research<\/h2>\n

Study objective:<\/strong>
\nResearchers evaluated whether different concentrations of CJC-1295 produced different growth hormone responses.<\/p>\n

Methodology:<\/strong>
\nParticipants received different peptide concentrations, while a comparison group received placebo. Researchers subsequently analyzed blood samples.<\/p>\n

Findings:<\/strong>
\nThe reported results indicated a concentration-dependent increase in growth hormone levels, with some experimental conditions producing substantially higher concentrations than placebo.<\/p>\n

Scientific significance:<\/strong>
\nThe research provides evidence for investigating the relationship between GHRH receptor stimulation and circulating growth hormone concentrations.<\/p>\n

It also highlights the connection between growth hormone and IGF-1<\/strong>, which researchers commonly evaluate as a downstream growth-factor signal.<\/p>\n

\n

GHRP-6 and Growth Hormone Research<\/h2>\n

Study objective:<\/strong>
\nResearchers examined the growth hormone response associated with GHRP-6 exposure.<\/p>\n

Methodology:<\/strong>
\nExperimental subjects received GHRP-6 either alone or alongside arginine, which researchers commonly study as a modulator of growth hormone secretion.<\/p>\n

Findings:<\/strong>
\nThe research reported increases in growth hormone concentrations following GHRP-6 exposure, with comparable responses observed across the experimental conditions.<\/p>\n

Scientific significance:<\/strong>
\nThese findings support continued investigation of GHRP-6 as a growth hormone secretagogue and provide context for studying its interaction with other growth hormone signaling pathways.<\/p>\n

\n

CJC-1295 and GHRP-6 Research in Thyroid-Related Models<\/h2>\n

Researchers have also investigated interactions between GHRH\/GHRP signaling and thyroid status.<\/p>\n

Study objective<\/h3>\n

The research examined growth hormone responses to GHRH, GHRP-6, and combinations of these signaling agents in subjects with altered thyroid function.<\/p>\n

M\u00e9thodologie<\/h3>\n

Experimental groups received individual peptides or combinations, after which researchers assessed growth hormone responses.<\/p>\n

R\u00e9sultats<\/h3>\n

The reported results indicated that combining GHRH-related signaling with GHRP-6 produced a stronger growth hormone response than some individual treatments.<\/p>\n

Scientific significance<\/h3>\n

These observations are relevant to research into the relationship between thyroid hormones, somatostatin, GHRH, and GHRP signaling.<\/p>\n

However, these findings should not be interpreted as evidence that the CJC-1295 & GHRP-6 blend is an established treatment for thyroid disorders.<\/p>\n

\n

CJC-1295 & GHRP-6 Research and Cellular Signaling<\/strong><\/h2>\n

GHRP-6 and Gastrointestinal Cellular Research<\/h2>\n

Researchers have investigated GHRP-6 in experimental models involving gastrointestinal cellular function.<\/p>\n

Some laboratory studies reported changes in intestinal epithelial activity and cellular migration following exposure to growth hormone secretagogues.<\/p>\n

Researchers have also explored the potential involvement of CD36<\/strong>, a membrane-associated receptor expressed by several cell types, including certain muscle, immune, and adipose cells.<\/p>\n

Because CD36 participates in lipid metabolism, inflammatory signaling, and vascular biology, its relationship with GHRP-6 remains an area of scientific interest.<\/p>\n

Scientific significance<\/h3>\n

These findings provide a basis for investigating how growth hormone secretagogues may interact with cellular signaling systems beyond the pituitary.<\/p>\n

They do not establish a therapeutic gastrointestinal application for GHRP-6.<\/p>\n

\n

GHRP-6 and Gastrointestinal Transit Research<\/h2>\n

Experimental research has investigated whether GHRP-6 influences gastrointestinal motility in animal models with altered metabolic conditions.<\/p>\n

Researchers reported changes in gastric emptying and intestinal transit following peptide exposure, while some aspects of colonic transit did not demonstrate the same response.<\/p>\n

Scientific significance<\/h3>\n

These observations indicate that growth hormone secretagogue signaling may interact with gastrointestinal regulatory pathways. Additional research is necessary to clarify the underlying mechanisms and their relevance outside experimental models.<\/p>\n

\n

CJC-1295 and Cardiac Research<\/h2>\n

Researchers have also studied GHRH analogs, including compounds related to CJC-1295, in experimental cardiac models.<\/p>\n

These investigations have examined processes such as:<\/p>\n